Literature DB >> 7682293

Neurotoxicity of peptide analogues of the transactivating protein tat from Maedi-Visna virus and human immunodeficiency virus.

M Hayman1, G Arbuthnott, G Harkiss, H Brace, P Filippi, V Philippon, D Thomson, R Vigne, A Wright.   

Abstract

Infection by lentiviruses such as human immunodeficiency virus, Maedi-Visna virus and Caprine Arthritis Encephalitis Virus, is associated with a variety of neurological syndromes, but the mechanism by which the damage occurs to the nervous system is not known. The viruses do not infect neurons and so the neurotoxic actions must be mediated indirectly. Here we applied synthetic peptide analogues derived from basic regions of Maedi-Visna virus and human immunodeficiency virus transactivating protein, tat, to rat brain in vivo and found them to be potent neurotoxins. The toxicity of the Maedi-Visna virus peptide was demonstrated to be reduced by blockade of nitric oxide synthase and of N-methyl-D-aspartate channel opening. These experiments suggest that peptides derived from lentiviral tat may share a common neurotoxic action.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682293     DOI: 10.1016/0306-4522(93)90278-n

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  30 in total

1.  Acceleration of HIV dementia with methamphetamine and cocaine.

Authors:  A Nath; W F Maragos; M J Avison; F A Schmitt; J R Berger
Journal:  J Neurovirol       Date:  2001-02       Impact factor: 2.643

2.  HIV-1 Tat protein promotes neuronal dysfunction through disruption of microRNAs.

Authors:  J Robert Chang; Ruma Mukerjee; Asen Bagashev; Luis Del Valle; Tinatin Chabrashvili; Brian J Hawkins; Johnny J He; Bassel E Sawaya
Journal:  J Biol Chem       Date:  2011-09-28       Impact factor: 5.157

3.  Human immunodeficiency virus tat gene transfer to the murine central nervous system using a replication-defective herpes simplex virus vector stimulates transforming growth factor beta 1 gene expression.

Authors:  S Rasty; P Thatikunta; J Gordon; K Khalili; S Amini; J C Glorioso
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

4.  Cell-specific actions of HIV-Tat and morphine on opioid receptor expression in glia.

Authors:  Jadwiga Turchan-Cholewo; Filomena O Dimayuga; Qunxing Ding; Jeffrey N Keller; Kurt F Hauser; Pamela E Knapp; Annadora J Bruce-Keller
Journal:  J Neurosci Res       Date:  2008-07       Impact factor: 4.164

Review 5.  Amphetamine toxicities: classical and emerging mechanisms.

Authors:  Bryan K Yamamoto; Anna Moszczynska; Gary A Gudelsky
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 6.  Rodent models of HAND and drug abuse: exogenous administration of viral protein(s) and cocaine.

Authors:  Honghong Yao; Shilpa Buch
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-24       Impact factor: 4.147

7.  Maturing neurons are selectively sensitive to human immunodeficiency virus type 1 exposure in differentiating human neuroepithelial progenitor cell cultures.

Authors:  Micheline McCarthy; Irving Vidaurre; Rebeca Geffin
Journal:  J Neurovirol       Date:  2006-10       Impact factor: 2.643

8.  The maedi-visna virus Tat protein induces multiorgan lymphoid hyperplasia in transgenic mice.

Authors:  C Vellutini; V Philippon; D Gambarelli; N Horschowski; K A Nave; J M Navarro; M Auphan; M A Courcoul; P Filippi
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

Review 9.  Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention--A Comparison with Parkinson's Disease.

Authors:  S DeVaughn; E M Müller-Oehring; B Markey; H M Brontë-Stewart; T Schulte
Journal:  Neuropsychol Rev       Date:  2015-11-17       Impact factor: 7.444

10.  Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoir.

Authors:  Xin Lin; Dan Irwin; Satoshi Kanazawa; Laurence Huang; Joseph Romeo; T S Benedict Yen; B Matija Peterlin
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.